ES2663836T3 - Carboxamidas de quinolina para su uso en el tratamiento de leucemia - Google Patents
Carboxamidas de quinolina para su uso en el tratamiento de leucemia Download PDFInfo
- Publication number
- ES2663836T3 ES2663836T3 ES15790143.0T ES15790143T ES2663836T3 ES 2663836 T3 ES2663836 T3 ES 2663836T3 ES 15790143 T ES15790143 T ES 15790143T ES 2663836 T3 ES2663836 T3 ES 2663836T3
- Authority
- ES
- Spain
- Prior art keywords
- day
- leukemia
- dihydroquinolin
- oxo
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776 | 2014-11-19 | ||
| EP14193776 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2663836T3 true ES2663836T3 (es) | 2018-04-17 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15790143.0T Active ES2663836T3 (es) | 2014-11-19 | 2015-11-05 | Carboxamidas de quinolina para su uso en el tratamiento de leucemia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (enExample) |
| EP (1) | EP3180005B1 (enExample) |
| JP (1) | JP6715833B2 (enExample) |
| KR (1) | KR102525805B1 (enExample) |
| CN (1) | CN107072989B (enExample) |
| AU (1) | AU2015348778B2 (enExample) |
| BR (1) | BR112017009854B1 (enExample) |
| CA (1) | CA2967112C (enExample) |
| EA (1) | EA031643B1 (enExample) |
| ES (1) | ES2663836T3 (enExample) |
| IL (1) | IL252174B (enExample) |
| MX (1) | MX379401B (enExample) |
| NZ (1) | NZ732704A (enExample) |
| PL (1) | PL3180005T3 (enExample) |
| WO (1) | WO2016078921A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168070A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| AU2021313388A1 (en) | 2020-07-23 | 2023-01-19 | Erasmus University Medical Center Rotterdam (Erasmus Mc) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| PL4277628T3 (pl) * | 2021-01-18 | 2026-02-09 | Active Biotech Ab | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
| JP2024520307A (ja) | 2021-05-25 | 2024-05-24 | アクティブ バイオテック エイビー | 複数のタスキニモド粒子およびその使用 |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| EP2590949B1 (en) | 2010-07-09 | 2015-11-25 | Active Biotech AB | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791099A1 (ru) | 2017-10-31 |
| NZ732704A (en) | 2022-01-28 |
| KR20170083121A (ko) | 2017-07-17 |
| MX2017006110A (es) | 2017-07-27 |
| IL252174B (en) | 2021-02-28 |
| AU2015348778A1 (en) | 2017-06-29 |
| BR112017009854B1 (pt) | 2022-08-23 |
| EP3180005A1 (en) | 2017-06-21 |
| KR102525805B1 (ko) | 2023-04-25 |
| PL3180005T3 (pl) | 2018-06-29 |
| CN107072989B (zh) | 2020-07-03 |
| BR112017009854A2 (pt) | 2018-01-16 |
| MX379401B (es) | 2025-03-11 |
| CN107072989A (zh) | 2017-08-18 |
| US10300053B2 (en) | 2019-05-28 |
| CA2967112A1 (en) | 2016-05-26 |
| JP2017534652A (ja) | 2017-11-24 |
| JP6715833B2 (ja) | 2020-07-01 |
| WO2016078921A1 (en) | 2016-05-26 |
| IL252174A0 (en) | 2017-07-31 |
| EP3180005B1 (en) | 2017-12-27 |
| CA2967112C (en) | 2023-05-16 |
| EA031643B1 (ru) | 2019-01-31 |
| AU2015348778B2 (en) | 2020-12-24 |
| US20170319568A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
| JP2015110588A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016528301A5 (enExample) | ||
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2016508134A5 (enExample) | ||
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
| MY204380A (en) | Nonracemic mixtures and uses thereof | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| MX2021009909A (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| JP2016522254A5 (enExample) | ||
| MY204827A (en) | Semaglutide in medical therapy | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| KR102525805B1 (ko) | 백혈병 치료용 퀴놀린 카르복사미드 | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| MX2020005006A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. |